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Abstract: Introduction: Magnesium is an essential cation involved in many functions within the central
nervous system, including transmission and intracellular signal transduction. Several studies have
shown its usefulness in neurological and psychiatric diseases. Furthermore, it seems that magnesium
levels are lowered in the course of several mental disorders, especially depression. Objectives: In this
study, we wish to evaluate the presence of a relationship between the levels of magnesium and
the presence of psychiatric pathology as well as the effectiveness of magnesium as a therapeutic
supplementation. Methods: A systematic search of scientific records concerning magnesium in
psychiatric disorders published from 2010 up to March 2020 was performed. We collected a
total of 32 articles: 18 on Depressive Disorders (DD), four on Anxiety Disorders (AD), four on
Attention Deficit Hyperactivity Disorder (ADHD), three on Autism Spectrum Disorder (ASD),
one on Obsessive–Compulsive Disorder (OCD), one on Schizophrenia (SCZ) and one on Eating
Disorders (ED). Results: Twelve studies highlighted mainly positive results in depressive symptoms.
Seven showed a significant correlation between reduced plasma magnesium values and depression
measured with psychometric scales. Two papers reported improved depressive symptoms after
magnesium intake, two in association with antidepressants, compared to controls. No significant
association between magnesium serum levels and panic or Generalized Anxiety Disorder (GAD)
patients, in two distinct papers, was found. In two other papers, a reduced Hamilton Anxiety Rating
Scale (HAM-A) score in depressed patients correlated with higher levels of magnesium and beneficial
levels of magnesium in stressed patients was found. Two papers reported low levels of magnesium
in association with ADHD. Only one of three papers showed lower levels of magnesium in ASD.
ED and SCZ reported a variation in magnesium levels in some aspects of the disease. Conclusion:
The results are not univocal, both in terms of the plasma levels and of therapeutic effects. However,
from the available evidence, it emerged that supplementation with magnesium could be beneficial.
Therefore, it is necessary to design ad hoc clinical trials to evaluate the efficacy of magnesium alone
or together with other drugs (antidepressants) in order to establish the correct use of this cation with
potential therapeutic effects.
Keywords: magnesium; mental disorders; depression; bipolar disorder; schizophrenia; obsessive-compulsive
disorder; autism; anxiety disorder; eating disorder
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1. Introduction
Psychiatric disorders are estimated to affect more than one billion people worldwide [1] and
recent reports claimed that the global burden of mental illness accounts for as many as one-third of
years lived with disability (YLDs) and 13% of disability-adjusted life years (DALYs) [2]. These figures
are associated with a high economic burden since the global direct and indirect economic costs of
mental disorders are estimated to be 2.5 trillion USD [3].
The therapeutic options for treating psychiatric disorders are progressively expanding, with both
pharmacologic and non-pharmacologic treatments becoming available in recent years. Moreover,
although the majority of drugs currently used to treat the more common psychiatric disorders have been
proven to be effective by recent robust meta-analyses [4,5], most of the psychiatric pharmacotherapy
must be continued for years (or even lifelong), bringing severe adverse side effects [6,7]. Furthermore,
the last decade has seen a steep increase in the price of both brand and generic psychiatric prescription
drugs [8] and therefore there is a greater need for new therapeutic options that prove to be effective,
safe and affordable for the patient and the healthcare system.
Oral nutritional supplements have been shown to improve clinical outcomes of hospitalized
patients [9] and to be cost-effective interventions [10]. In recent years, there has been a surge in the
number of studies performed in the field of the so-called Nutritional Psychiatry [11], where researchers
have been focusing not only on the effects of general dietary modifications on some psychiatric
illnesses, in particular mood disorders [12], but also on the potential role of supplementation of single
micronutrients in patients with mental disorders [13]. The most substantial pieces of evidence on
the efficacy of these interventions are probably those coming from n-3 polyunsaturated fatty acids
(n-3PUFAs) supplementation in depression [14,15], which, in a few years, will likely become part of
the standard therapy for depression [16].
Among micronutrients, magnesium (Mg2+) plays a critical role in brain function and mood
since it is essential for optimal nerve transmission and it is involved in the formation of membrane
phospholipids. For this reason, it plays a fundamental role in the correct functioning of the central
nervous system [17,18].
Specifically, for psychiatric illnesses, multiple studies have been performed in which magnesium
serum levels were assessed in cohorts of patients with depression [19], SCZ [20], addiction disorders [21],
AD [22] and ADHD [23].
Magnesium has also been studied, both in the form of enriched diet and supplementation at high
doses, as an adjunct therapy for psychiatric disorders, in particular in anxiety [24] and mood [25]
disorders. However, results from reports on both magnesium levels and supplementation in psychiatric
illnesses are often conflicting, potentially due to methodological heterogeneity, which involves,
among others, measuring techniques (extracellular vs. ionized magnesium) [26] and supplementation
modalities (dose, posology, magnesium form used).
Since magnesium could represent a potentially novel adjunctive therapy in mental disorders,
with this review, we aim to give a comprehensive picture of the relationship between magnesium and
psychiatric disorders. In particular, we will try to answer the following questions: (a) Are magnesium
levels altered in patients with psychiatric disorders? (b) Is magnesium supplementation effective
and safe in patients suffering from mental illnesses? If so, is it possible to identify a preferred dose,
posology or element form?
To answer these questions, we performed a comprehensive review in which we included all
studies that involved patients with a wide variety of psychiatric disorders where magnesium levels
were assessed and/or magnesium supplementation was given.
Biological Plausibility of Magnesium for Brain and Psychiatric Disorders
Magnesium is the fourth most abundant mineral ion, and the intake comes mainly from the
ingestion of leafy green vegetables, whole grains, nuts, and fish. Magnesium is absorbed in the
gastrointestinal tract and the renal system. This element facilitates calcium (Ca2+) absorption and
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both ions are regulated by the parathyroid hormone; however, free ion concentration does not always
correlate with total concentration. Magnesium is primarily found within the cells, while extracellular
magnesium accounts for ∼1% of total body magnesium. Furthermore, serum magnesium is present in
three forms, with ionized magnesium having the highest biological activity [27].
Magnesium is essential to ensure the correct functioning of all human cells, neurons included; it is
involved, among others processes, in hundreds of enzymatic reactions [28], intracellular transmission [29],
myelination process [30], synapses formation and maintenance [31] as well as in the regulation of
serotoninergic, dopaminergic and cholinergic transmission [32]. Magnesium is, therefore, an element
necessary to maintain neurons healthy and viable [33], especially because it has been shown to reduce
apoptosis in an animal model of induced hypoxia-ischemia [34] and to prevent synaptic loss in a mouse
model of Alzheimer disease [35,36]. Shreds of evidence also suggest that magnesium is involved in
neurogenetic processes and the maturation of newly generated neural cells; in fact, magnesium has
been proven to efficiently enhance the proliferation of neural stem cells [37] and neurite outgrowth [38].
Through the induction of synaptic plasticity and potentiation of synaptic transmission in the rat
hippocampus, magnesium has also been shown to enhance learning abilities, working memory and
short- and long-term memory [39].
The antidepressant action of magnesium is likely to be mediated by several mechanisms. The most
important one seems to be the one involving the blockade of the glutamatergic N-methyl-D-aspartate
receptor (NMDAR); interestingly, this is the same target of the fast-acting antidepressant ketamine,
an NMDAR antagonist as well. However, other components of glutamatergic transmission, such as the
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid AMPA receptor, appear to be modulated by
magnesium as well [40]. Another relevant finding that supports the notion of magnesium antidepressant
activity is the one linking magnesium deficiency to dysregulation in the hypothalamic–pituitary–adrenal
(HPA) axis, which is well known to be involved in the pathogenesis of anxiety disorders and
depression [41]. Conversely, increased levels of brain magnesium have been shown to enhance (a) the
retention of the extinction of fear memory, through increased NMDA signaling, (b) the brain-derived
neurotrophic factor (BDNF) expression and (c) synaptic plasticity in the prefrontal cortex (PFC); notably,
these effects were absent in another region closely linked to depression pathogenesis, such as the
basolateral amygdala [42].
The antidepressant action of magnesium appears to be, at least partially, mediated by a modulation
of the serotoninergic system; in fact, it seems that magnesium has a synergistic effect when administered
with molecules of the selective serotonin reuptake inhibitor (SSRI) class and that the antidepressant
action of magnesium is impaired when animals are pre-treated with a compound that inhibits the
serotonin synthesis [43]. Interestingly, in rats, a diet deficient in magnesium was also found to be
associated with alterations in the gut microbiota, ultimately leading to alterations in the gut-brain
axis and the development of depressive-like behaviors [44]. Finally, Sowa-Kuæma et al. [45] found
that concentrations of both magnesium and zinc (Zn) were reduced in the hippocampal tissue of
suicide victims, along with an altered glutamatergic NMDA activity in the hippocampus. Moreover,
several reports suggest that magnesium is a key mediator of the efficacy of antipsychotic medications.
Both haloperidol and risperidone were found to increase intra-erythrocytic magnesium levels [46]
and treatment of hypoparathyroidism-induced psychosis seems to be dependent on magnesium level,
with hypomagnesemia causing treatment resistance to antipsychotics [47]. Magnesium also appears to
be involved in both prevention and reversal of movement disorders induced by the chronic use of
typical antipsychotics. Moreover, in an animal model, magnesium was found to reduce the severity of
movement disorders via the prevention of the formation of reactive oxygen species in cortical areas,
striatum and substantia nigra [48].
2. Materials and Methods
A comprehensive search of all studies using or analyzing the effect of magnesium in psychiatric
disorders were conducted on the PubMed database from 1 January 2019 to 30 March 2020.
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The search was re-run on a weekly basis, with the last search performed on 10 April 2020. Finally,
we searched for potentially valuable records by scanning reference lists of articles relevant to the topic.
The final search strategy for PubMed was designed by AB and the search syntax is reported in the
Supplementary Materials.
Articles of potential interest were identified by using the following search strategy: “(magnesium
OR Mg2+) AND (psychiatric disorders OR mental diseases OR psychotic disorders OR psychosis
OR ultra-high risk psychosis OR schizophrenia OR bipolar disorder OR affective disorder OR major
depressive disorder OR depression OR personality disorder OR anxiety disorders OR obsessive
compulsive disorders OR eating disorders OR ADHD OR autism)”. Only studies in English (or
with an English translation available) were taken into consideration. Relevant articles were obtained
and included in the review if (a) they reported an exposure to magnesium, (b) included psychiatric
symptoms as an outcome measure and (c) enrolled human participants and reported a trial or an
observational study. We considered cohort studies by exploring serum levels of magnesium as primary
outcome and trials in which the authors used an exposure of magnesium alone or as an adjunctive
therapy to other drugs (e.g., antipsychotic, antidepressants, mood stabilizers and benzodiazepines),
or other non-pharmacological strategies, such as psychotherapy and physical exercise compared to
placebo or pharmacotherapy alone. In addition, we included trials that employed a diet enriched in
magnesium as a supplementation. All the studies, both clinical trials and cohort studies (prospective
or retrospective), reporting the effects of magnesium in patients were included.
To limit the heterogeneity of this review and to reduce selection bias, we decided to exclude:
(1) studies that did not explore the effects of magnesium on psychiatric symptoms as primary outcome;
(2) pre-clinical studies, both in vitro and in vivo (animal); (3) case-control, case series or case reports;
(4) reviews and/or metanalyses.
Search results were exported into the reference manager software “Rayyan QCRI”; duplicates detected
by the software were resolved manually by (AB). After duplication removal, all the resulting records
were screened by title and abstract by AB and BV and initially labeled for inclusion with “included”,
“excluded” or “maybe”. Inclusion of records labeled with “maybe” was discussed between the two
reviewers, with other members of the team involved if needed. In the second level of screening,
full text of publications was evaluated by AB and BV; disagreements on study selection were resolved
by consensus with the involvement of a third author (VC). Two reviewers (AB and BV) independently
charted the data and discussed the results; any disagreement was resolved by consensus with the
involvement of a third team member (VC). Since the search was re-run on a weekly basis, data from
newly included study were updated accordingly. Then data items collected were analyzed according
to the following variables that were abstracted for each article (see Supplementary Materials).
The results were grouped based on whether they were observational or clinical trials investigating
the effect of magnesium on patients’ mental health. Findings were discussed on the basis of different
diagnoses made (e.g., depression, schizophrenia) and are summarized in table form. The results for
each clinical topic are presented in a narrative form in the main text.
We identified 1104 citations by searching the PubMed database. After duplicates were removed,
a total of 698 records were considered for inclusion. After the first screening, based on the title and
abstract, 621 records were excluded, with 77 full text articles to be retrieved and assessed for eligibility.
After this second screening process, 45 studies were excluded for the following reasons: 11 were animal
studies; seven did not report the effect of magnesium as primary outcomes; 18 did not report as results
the serum levels of magnesium; three were reviews or metanalyses; four were preclinical studies
and two did not investigate an adult sample. Finally, a total of 32 articles were considered eligible
for this review. The process of the identification and inclusion of trials is summarized in Figure 1
(PRISMA diagram).
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Figure 1. PRISMA (2009) flow diagram [49].
Relevant articles were obtained and included in the review if (a) they reported an exposure to
magnesium, (b) included psychiatric symptoms as an outcome measure, and (c) enrolled human
participants and reported a trial.
3. Results
Most of the results of the reviewed studies focused on depression and depressive symptoms and
only a small number of studies concerning other psychiatric disorders were found.
.1. Depression
Risk factors for depression includ dietary patterns. Some epidemiological or observational studies
reported that great r dietary intake of magnesium is linked to a general reduced risk of depressive
disorders or fewer depressive symptoms [50,51]. However, some studies also suggested that,
in depressive disorders, magnesium plasma levels can show different or synergistic effects [52].
To clarify this issue, in this paragraph we reviewed all randomized clinical trial (RCT) studies,
exploring the impact of magnesium on depressive disorders. Firstly, we explored the RCT studies
(Table 1) that explored magnesium levels in depressed patients. We identified twelve studies showing
mainly positive results, even though they were conducted in different populations and measured
symptoms with various tools.
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Table 1. Studies of magnesium levels.
Author, Year Title Sample Study Type PsychiatricDisorder Psychopathological Scale Results
Direction of
Evidence
[53]
Total and ionized calcium and magnesium are
significantly lowered in drug-naïve depressed
patients: effects of antidepressants and
associations with immune activation
(a) 140 MDD + 40 hc; treatment
in 48 MDD;
(b) 44 patients, 2 months with
blood samplings (baseline and
during treatment)
(a) case-control study;
(b) prospective study Depression BDI-II
In MDD patients Serum Ca and Mg (total and ionized)
were significantly lower compared with controls.
Antidepressants increased Ca and lowered Mg levels.
Significant and inverse correlations between the BDI-II
scores from baseline to endpoint and Ca (both total and
ionized), but not Mg levels. Antidepressants probably
reduced Mg levels as a side effect
(+)
[54] Biomarkers in Drug Free Subjects withDepression: Correlation with Tryptophan 96 (48 depression, 48 controls) cross-sectional study Depression HAMD
Depression is associated with deficiency of TRP, Se, Vit
D, Mg. (The association among TRP and other
biomarkers is non-significant)
(+)
[55]
Comparative analysis of serum zinc, copper,
manganese, iron, calcium, and magnesium level
and complexity of interelement relations in
generalized anxiety disorder patients
50 GAD, 51 hc comparative study GAD DSM-IV criteria Ca and Mg concentration between patient and controlgroups were not significant (p> 0.05) (−)
[56]
Alterations of serum macro-minerals and trace
elements are associated with major depressive
disorder: a case-control study
247 patients and 248 prospectivecase-control study Depression DSM-5 criteria
Decreased concentrations of Ca and Mg, Fe, manganese,
selenium, and zinc in MDD patients compared with
control subjects. Data obtained from different
inter-element relations in MDD patients and control
subjects strongly suggest that there is a disturbance in
the element homeostasis
(+)
[57] Serum Vitamin D and Magnesium levels in apsychiatric cohort
73 psychiatric day treatment
unit cohort
cross-sectional
analysis Miscellaneous ICD-10 criteria
The percentage of patients who were magnesium
deficient was 78.6% (n = 22/28) (+)
[58] Depression in elderly type 2 diabetes 210 type 2 diabetes patientsaged 65 years and above cross-sectional study
Depression in
elderly type 2
diabetes
DSM-IV criteria
Among all patients, 88.6% had magnesium intake which
was less than the dietary reference intake, and 37.1%
had hypomagnesaemia. The odds of depression, central
obesity, high body fat percentage, and high body mass
index were significantly lower with increasing quartile
of magnesium intake (p for trend < 0.05). The majority
of elderly type 2 diabetes who have low magnesium
intake may compound this deficiency with metabolic
abnormalities and depression
(+)
[59] Low dietary calcium is associated with self-rateddepression in middle-aged Korean women
105 women age 41–57; 51
pre-meno-pausal, 54
post-meno-pausal
case-control study
Depression in
middle-aged
women
SDS
No significant differences in serum levels of Ca and Mg
among the three groups with different severity of
symptoms. Negative correlations between SDS and Ca
intake and animal Ca after adjusting for age,
menopause and energy intake
(−)
[60]
Correlation between Depression with Serum
Levels of Vitamin D, Calcium and Magnesium in
Women of Reproductive Age
100 women 15–44 years old cross-sectional study Depression BDI-II
Women’s depression scores showed a significant inverse
correlation with the serum level of vitamin D (r = -0.21,
p = 0.03). No significant correlations with serum levels
of calcium and magnesium
(−)
[61] Plasma magnesium levels and treatmentoutcome in depressed patients 123 outpatients observational study Depression
HAMD; HAMA;
(DRRS); (SHAPS)
No association between Mg levels and
psychopathological severity Patients who responded to
antidepressant treatment showed higher Mg levels and
higher retardation scores at basal evaluation in
comparison with non-responders
(−)
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Table 1. Cont.
Author, Year Title Sample Study Type PsychiatricDisorder Psychopathological Scale Results
Direction of
Evidence
[62] Variability in serum electrolytes in differentgrades of depression
100 MDD (age 35–45),
100 hc matched) cross-sectional study Depression DSM-IV, ICD-10 criteria; HAMD
All the depression patients were having higher level of
Na, K, and Ca and lower level of Mg. Multiple
comparison revealed highly statistically significant
difference between the levels of serum Ca and Mg in three
levels of severity (mild, moderate and severe depression)
(+)
[63]
Analysis of Relations Between the Level of Mg,
Zn, Ca, Cu, and Fe and Depressiveness in
Postmenopausal Women
198 healthy post-meno-pausal
women (age 56.26 ± 5.55) cross-sectional study Depression
Depressive symptoms in
postmenopausal women
Women with depressive symptoms had the lowest Mg
levels (14.28 ± 2.13 mg/l), the highest in women without
depressive symptoms (16.30 ± 3.51 mg/L), (p ≤ 0.05).
Authors indicate a higher vulnerability to depression in
a group of women with lower levels of Mg and higher
levels of Cu
(+)
[64]
The Association between Serum Magnesium
Levels and Depression in an Adult Primary
Care Population
3604 adults cross-sectional analysis Depression PHQ
The relationship between serum magnesium and
depression using univariate analyses showed a
significant effect when measured by the PHQ-2 (−0.19
points/mg/dL; 95% CI −0.31, −0.07; p = 0.001) and the
PHQ-9 (−0.93 points/mg/dL; 95% CI −1.81, −0.06; p =
0.037). This relationship was strengthened after
adjusting for covariates
(+)
[65] Screening depression in overweight and obesepregnant women and its predicts
232 overweight or obese
pregnant women cross-sectional study
Depression in
pregnancy
Edinburgh Postnatal
Depression Scale
Protein, fat, magnesium had positive significant
correlation with depression (+)
[66]
Comparative analysis of serum manganese, zinc,
calcium, copper and magnesium level in panic
disorder patients
54 panic disorder. + 52 hc comparative analysis Panic disorder DSM-IV criteria
Serum concentration of Zn decreased significantly (p =
0.001) in patient group. Otherwise concentration of Mn,
Ca, Cu, and Mg were not significant.
(−)
[67]
Hamilton anxiety scale (HAMA) in infertile
women with endometriosis and its correlation
with magnesium levels in peritoneal fluid
40 endo-metriosis, 47 hc
undergoing laparo-scopy (other
causes of infertility)
prospective study Anxiety disorders HAMA
In infertile women without endometriosis there was a
correlation between Mg concentration in peritoneal
fluid and HAMA score. No such correlation was found
in the women with endometriosis
(+)
[68]
Alterations of serum zinc, copper, manganese,
iron, calcium, and magnesium concentrations
and the complexity of interelement relations in
patients with obsessive-compulsive disorder
48 OCD + 48 hc cross-sectional study OCD Yale-Brown ObsessiveCompulsive Scale (YBOCS)
In patients’ serum, zinc, iron, and magnesium
concentrations decreased significantly (p < 0.05)
compared to the controls
(+)
[69]
Platelet and serum calcium and magnesium
concentration in suicidal and non-suicidal
schizophrenic patients
23 schizophrenics (ICD-10) with
attempted suicide + 48 without
suicidal behavior + 99 hc
cross sectional study,
with 3 groups used for
comparison
Suicidal and
non-suicidal
schizophrenic
patients
semi-structured interview
(ICD-10 criteria);
A higher Ca/Mg ratio in the platelets of non-suicidal
patients confirms indirect higher Ca concentration.
Higher Mg concentration in the platelets of suicidal
patients, considered a Ca antagonist, may represent a
compensatory attempt to restrain Ca activity
(±)
[70] Hypomagnesemia in adolescents with eatingdisorders hospitalized for medical instability
541 hospitalized adolescents
aged 10–21 years with an eating
disorder from 2007 to 2010
retrospective study Eating disorders DSM-IV criteria; clinicalcharacteristics
15.9% developed hypomagnesemia. Compared with
those with normal serum magnesium levels, patients
with hypomagnesemia were older (p = 0.0001), ill longer
(p = 0.001), more likely to be purging (p = 0.04), and
more likely to have an alkaline urine (p = 0.01). They
did not differ in eating disorder diagnosis, BMI, or other
electrolyte disturbances. Hypomagnesemia is prevalent
in adolescents hospitalized for an eating disorder and is
associated with purging and alkaline urine
(±)
[71]
Blood Levels of Trace Elements in Children with
Attention-Deficit Hyperactivity Disorder:
Results from a Case-Control Study
419 ADHD, 395 hc case-control study ADHD
Vanderbilt ADHD Diagnostic
Parent and Teacher Rating Scales,
Conners’ Parent and Teacher
Rating Scales (Chinese version),
SNAP-IV, Raven’s
Progressive Matrices.
Lower zinc levels (p < 0.001) and the number out of
normal ranges (p = 0.015) were found in children with
ADHD when compared with the normal control group.
The difference remained when adjusting the factor of
BMI z-score. No significant between-group differences
were found in levels of other elements
(+)
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Table 1. Cont.
Author, Year Title Sample Study Type PsychiatricDisorder Psychopathological Scale Results
Direction of
Evidence
[72]
Zinc, ferritin, magnesium and copper in a group
of Egyptian children with attention deficit
hyperactivity disorder
58 ADHD,
age 5–15 + 25 hc, matched case-control study ADHD
Conner’s Rating Scales,
discriminating between children
with ADHD and h.c., as well as
severity of ADHD.
Zinc, ferritin and Mg levels were significantly lower
than controls (p value 0.04, 0.03 and 0.02 respectively).
No significant differences between sub-groups of
ADHD
(+)
[73]
Serum zinc, copper, zinc-to-copper ratio, and
other essential elements and minerals in
children with attention deficit/hyperactivity
disorder (ADHD)
136 (children) (68 ADHD,
68 hc, matched) cross-sectional study ADHD CD-10 criteria (F90.0)
Cr, Mg, and Zn levels in children with ADHD were 21%
(p = 0.010), 4% (p = 0.005), and 7% (p = 0. 001) lower as
compared to the healthy controls, respectively.
However, the patterns of trace element and mineral
levels in ADHD were significantly affected by gender
and age. Hypothetically, the observed decrease in
essential trace elements, namely Mg and Zn, may
significantly contribute to the risk of ADHD or its
severity and/or comorbidity
(±)
[74]
Evaluation of Whole Blood Trace Element Levels
in Chinese Children with Autism
Spectrum Disorder
113 ASD children, 141 age- and
gender-matched neurotypical
children
ASD
No significant differences in the whole blood Cu, Zn/Cu
ratio, Fe, or Mg was detected between the ASD group
and the control group
(−)
[75]
Plasma concentrations of the trace elements
copper, zinc and selenium in Brazilian children
with autism spectrum disorder.
23 ASD cross-sectional study ASD DSM-5 criteria
The cohort did not show a marked difference in
micro-nutrient intake in relation with their resident
geographical area and their dietary habit or metabolic
state; a slight difference in the levels of magnesium and
phosphorus was retrieved due to sex difference
(−)
[76]
Vitamin and mineral status of children with
autism spectrum disorder in Hainan Province of
China: associations with symptoms.
274 ASD, 97 age-matched hc
(typically developed) Interventional study ASD
DSM-5 criteria; (ABC), (SRS),
(GDS)
The levels of Ca, Mg, Fe, and zinc in children with ASD
were significantly lower than those in TD children (+)
Captions: (MDD) Major depressive disorder; (hc) Healthy controls; (BDI-II) Beck Depression Inventory; (HAMD) Hamilton Depression Rating Scale; (TRP) tryptophan; (GAD) Generalized
Anxiety Disorders; (ICD-10) International Classification of Diseases, Tenth Revision; (SDS) Self-rating Depression Scale; (HAMA) Hamilton Anxiety Rating Scale; (DRRS) Depression
Retardation Rating Scale; (SHAPS) Snaith - Hamilton Pleasure Scale; (PHQ) Patient Health Questionnaire; (EPDS) Edinburgh Postnatal Depression Scale; (ABC) Autism Behavior Checklist;
(SRS) Social Responsiveness Scale; (GDS) Gesell Developmental Scale positive outcome (+); negative outcome (−); unclear result (±).
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Table 2. Socio-demographic and clinical details of all included studies investigating the effect of Mg as treatment.
Author,
Year Sample Study Type
Psychiatric
Disorder
Psycho-
Pathological Scale Treatment
Treatment
Duration Results Outcome
Direction of
Evidences
[77]
30 patients (7 M, 19 F; mean age
32.20 ± 9.54) + 30 hc (7 M, 20 F;
mean age 32.07 ± 7.69)
Double-blind, placebo-controlled trial Depression BDI-II Mg oxide 250 mg/die 8 weeks
BDI score significantly declined in
patients treated with Mg compared
to placebo.
Mg supplementation was effective
on depression status in depressed
patients with Mg deficiency
(+)
[78]
55 randomized to Immediate
treatment (22 M, 33 F; mean age
55.2 ± 12.3) + 57 randomized to
Delayed treatment (22 M, 35 F;
mean age 50.1 ± 13.0)
Randomized case-control clinical trial Depression PHQ-9, GAD-7 248 mg of elemental Mg/die 6 weeks
Clinically significant net improvement
in PHQ-9 scores of -6.0 points and
(GAD-7 in scores of -4.5 points.
Similar effects were observed
regardless of age, gender, baseline
severity of depression, baseline Mg
level, or use of antidepressants. Effects
were observed within two weeks.
Mg is effective for
mild-to-moderate depression
in adults
(+)
[79]
17 patients (6 M, 11 F; mean age
48.1±15.5) + 20 hc (10 M, 10 F;
mean age 49.7±12.3)
Placebo-controlled study and review Depression HAMD, HAMA,CGI
Fluoxetine (20 to 40 mg/die)
treatment was augmented with
either placebo or Mg 40 mg
×3/die (equivalent to 3.30 mEq
of Mg-aspartate)
8 weeks
Fluoxetine + Mg group showed
improvement in HDRS scores at
week 8 than the fluoxetine+placebo
group, but the difference was not
statistically significant.
No significant superiority of Mg
augmentation therapy on
depressive and anxiety symptoms
(±)
[80]
99 women (3 groups, mean age
29.4 ± 5.4, 26.4 ± 4.8, and 27.6 ±
5.1 respectively)
Randomized controlled clinical trial
Postpartum
Depression
and Anxiety
EPDS, SSTAI 27 mg Zn-sulfate or 320 mgMg-sulfate/die 8 weeks
No significant difference in EPDS
and SSTAI scores between groups.
Mg and zinc did not reduce
postpartum anxiety and
depressive symptoms
(−)
[81] 71 medication-free ADHD (55 M,16 F; mean age 9.7 ± 1.5) randomized clinical trial ADHD
ADHD-RS-IV, CGI,
CGAS
Broad spectrum micronutrient
formula (Daily Essential
Nutrients, DEN) up to
12 cp/die, vs placebo (no Mg
doses available)
10 weeks
Most children entered the trial with
nutrient levels falling within
expected ranges. Regression
analyses showed varying predictors
across outcomes with no one of the
predictors being consistently
identified across different variables.
Limited value of using serum
nutrient levels to predict treatment
response, although Authors
cannot rule out that other
non-assayed nutrient levels may
be more valuable
(±)
[82] 264 (69 M, 195 F; mean age31.6±8.5) Randomized, single-blind clinical trial
Depressive,
anxiety and
stress
symptoms
DASS-42
Mg–vitamin B6 combination,
respectively 300 mg/die and
30 mg/die
or Mg alone (Magnespasmyl)
300 mg/die
8 weeks
Both treatment arms reduced
DASS-42 stress subscale score from
baseline to Week 8. Adults with high
stress score had a 24% greater
improvement with Mg-vitamin B6
versus Mg at Week 8.
Mg supplementation alleviated
stress in healthy adults with
hypomagnesemia. Addition of
vitamin B6 to Mg was not superior
to Mg supplementation alone
(+)
[83] 12 patients (3 M, 9 F, mean age46.5±9) Double-blind crossover trial
Treatment-Resistant
Depression
PHQ-9,
HAMD
4 g Mg-sulfate/die in 5%
dextrose or placeboinfusion of
5% dextrose
8 days intervention
periods with a 5
days washoutin
between periods
No changes were recorded on the
HAMD or PHQ-9 24 h post-
treatment; serum Mg increased from
baseline to day 7, PHQ-9 decreased
from baseline to day 7.
Intravenous infusion of Mg-
sulfate did not reduce depressive
symptoms in adults with
treatment-resistant depression
(−)
Captions: (PHQ-9) Patient Health Questionnaire-9; (GAD-7) Generalized Anxiety Disorders-7; (EPDS) Edinburgh Postnatal Depression Scale; (SSTAI) Spielberger State-Trait Anxiety
Inventory; (ADHD-RS-IV) ADHD Rating Scale IV; (DASS-42) Depression Anxiety Stress Scales; (CGAS) Children Global Assessment Scale; (+) positive outcome; (−) negative outcome; (±)
unclear outcome.
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A group of studies investigated several microelements, including serum magnesium, in depressed
patients vs. healthy controls. Most studies reported a significant decrease in concentrations of
magnesium in depressed patients [53,54,56–58] whereas two studies [59,60], conducted in a female
population, reported no significant decrease in magnesium levels.
We identified three studies [61–63] that correlated magnesium levels with the severity of symptoms,
measured with a variety of tools, but reporting mixed results.
One study [61] showed only a small correlation between psychomotor retardation and magnesium
plasma levels. Interestingly, when patients were divided between responder and non-responder to
treatment (SSRI or SNRI), they demonstrated that patients with higher plasma magnesium levels at
baseline improved more compared to those with lower magnesium levels at baseline.
Finally, we identified two studies conducted on healthy populations, evaluating the correlation
between magnesium levels and depressive symptoms. Specifically, Tarleton et al. (2019) [64] considered
Patient Health Questionnaire (PHQ) scores in a large cohort of 3604 healthy adults and showed a
significant relationship between serum magnesium and symptoms. Similarly, Salehi-Pourmehr et
al. (2019) [65], who conducted a study on overweight pregnant women, also reported a positive
significant correlation.
Furthermore, we identified five RCT studies (Table 2) in which magnesium was administered
alone or as an add-on treatment to depressed patients, also reporting contrasting results. Specifically,
we found three positive studies showing the efficacy of magnesium supplementation in the treatment
of depression [77,78,82]. In contrast, Fard et al. (2017) [80] showed that magnesium did not reduce
anxiety and depressive symptoms in postpartum women. In the same direction, Mehdi et al. (2017) [83]
did not find a significant effect of magnesium sulfate in affecting depression.
Finally, a single, smaller study [79] addressing the efficacy and safety of magnesium as an
augmentation to antidepressant treatment, found no significant differences.
In conclusion, current evidence on the impact of magnesium on depression should be
supported using longitudinal studies with extended follow up, larger sample sizes and repeated
psychopathological evaluations at different times.
3.2. Other Psychiatric Disorders
3.2.1. Anxiety Disorders
In our record screening process, we identified four studies that analyzed the concentration
of magnesium in patients suffering from anxiety disorders. Three of them reported no significant
differences in magnesium serum levels in Generalized Anxiety Disorder (GAD), Panic Disorder and
anxiety symptoms during a major depressive episode [55,61,66]. In contrast, in Camardese et al.
(2012) [61], the authors hypothesized that hypomagnesaemia could play a role in drug responsiveness
among depressed patients, as they found a correlation between lower magnesium levels and poor
outcomes in treated patients.
Garalejic´ et al. (2010) [67] also investigated the relationship between Hamilton Anxiety Scale
(HAMA) scores and magnesium levels, although, unlike other studies identified, this study considered
magnesium levels in peritoneal fluid among 87 infertile women undergoing laparoscopy, finding a
strong negative correlation between the severity of anxiety symptoms and magnesiumg concentration
in peritoneal fluid. Therefore, the authors hypothesized that the decrease in magnesium peritoneal
concentration may be caused by the higher production of endogenous catecholamines (predominantly
adrenaline) in patients showing higher scores at the anxiety symptoms assessment.
Finally, as for the use of magnesium supplementation in psychopharmacological treatment,
we found one study that considered the effects of magnesium supplementation on anxiety
symptoms [80]. As depicted above, Fard et al. (2017) [80] explored both the baseline trace element
level and possible benefits of Zn and Mg2+ supplements on depression and anxiety symptoms among
postpartum women. Anxiety symptoms were evaluated using the Spielberger State–Trait Anxiety
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Inventory and no statistically significant difference was observed in mean scores of state anxiety and
trait anxiety.
3.2.2. Obsessive–Compulsive Disorder (OCD)
There are very few scientific data about serum levels of microelements in Obsessive–Compulsive
Disorder (OCD) patients. Indeed, we found only one study carried out by Shohag et al. (2012) [68]
that described a decrease in magnesium levels, together with Zn and Fe levels, in OCD patients when
compared to healthy controls.
3.2.3. Schizophrenia
We found a total of one study concerning Mg and SCZ (Table 1). Specifically, Jabotinsky-Rubin et al.
(1993) [84] reported that patients with SCZ had increased magnesium plasma concentrations and also
that magnesium levels were reduced after the administration of haloperidol. In contrast, Athanassesnas
et al. (1983) [85] reported no differences in plasma magnesium concentrations in drug-free patients
with SCZ. Moreover, in our record screening process, we found one study, carried out by Ruljancic et al.
(2013) [69], that studied magnesium concentration in suicidal and non-suicidal patients with SCZ,
which reported a higher magnesium concentration in the platelets of suicidal patients and a higher
Ca2+/Mg2+ ratio in the platelets of non-suicidal patients, an indirect index of higher Ca2+ concentration.
However, the imbalance found in the two electrolytes in the platelets of suicidal and non-suicidal
patients with SCZ still requires further research in order to clarify the involvement of Mg and Ca2+ in
SCZ, as well as a possible relation to antipsychotic action.
3.2.4. Eating Disorders
A large retrospective study by Raj et al. (2012) [70] aimed to determine the prevalence of
hypomagnesemia (Mg2+ ≤ 1.7 mg/dL) and clinical characteristics of adolescents hospitalized with a
DSM-IV [86] diagnosis of eating disorder. As expected, they found hypomagnesemia in approximately
16% of eligible participants. Furthermore, the authors found that, compared to those with normal
serum magnesium levels, patients with hypomagnesemia were older, with longer illness durations,
more likely to be purging, and more likely to have an alkaline urine. However, they did not differ in
eating disorder diagnosis, Body Mass Index, or other electrolyte disturbances.
3.2.5. Attention Deficit Hyperactivity Disorder (ADHD)
In recent years, some studies [87] have explored the association between micronutrient dietary
intake and ADHD development. Specifically, Rucklidge et al. (2019) [81] (Table 1) conducted a parallel
group RCT to assess the efficacy and safety of a broad-spectrum micronutrient formula compared with
a placebo in 93 medication-free children diagnosed with ADHD. With regard to micronutrient levels
among the subjects, most children entered the trial with nutrient blood levels falling within expected
ranges. Data analysis only resulted in statistically insignificant associations between micronutrient
treatment response and pre-treatment serum nutrient levels, showing the limited value of using serum
nutrient levels to predict treatment response.
Moreover, Yang et al. (2019) [71] (Table 1) conducted a study with the aim of investigating the trace
element status of Zn, Cu, Fe, Mg2+ and lead in children with ADHD and healthy controls. They enrolled
Chinese children diagnosed with ADHD, according to DSM-5 criteria [88], under the following
three presentations: predominantly inattentive presentation, predominantly hyperactive/impulsive
presentation and combined presentation; they were between the ages of 6 and 16 years and had no
history of psychopharmacological treatment for their condition. The authors found that there were
alterations in the blood levels of Zn in ADHD patients, which were associated with their symptom
scores. However, unlike Zn levels, the study failed to find a correlation between magnesium and
ADHD diagnosis or symptom scores.
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In contrast, in a case-control study, Mahmoud et al. (2011) [72] found that magnesium levels were
significantly lower in children with ADHD compared to controls. Finally, in a very recent publication,
Skalny et al. (2020) [73] also observed a significant difference in magnesium between ADHD patients
and gender- and age-matched neurotypical controls. However, the patterns of trace element and
mineral levels in ADHD were significantly affected by gender and age.
3.2.6. Autism Spectrum Disorder (ASD)
Regarding the role of trace elements in this group of disorders, two studies did not find a
statistically significant difference in levels of magnesium in children diagnosed with Autism Spectrum
Disorder (ASD) compared to age-matched and gender matched neurotypical children [74,75] (Table 1),
while one study [76], demonstrated lower levels of Mg in a large cohort of Chinese children diagnosed
with ASD.
4. Discussion
The aim of this review was to provide a comprehensive overview of the effects of magnesium in
different psychiatric disorders. Interestingly, from the reviewed studies, it emerged that the results
showing an association between mental disorders and magnesium are still largely inconclusive.
Specifically, we found a great number of studies evaluating serum levels of magnesium in different
mental disorders, especially depression. However, only few RCTs tested the efficacy of magnesium
alone or as an added therapy in the treatment of different psychiatric disorders and only two studies
explored the presence of magnesium in the dietary habits of a schizophrenic and depressed population,
respectively. Notably, the presence of many studies on depression is not surprising since the use
of magnesium is mostly reserved to depressive disorders, because of its involvement in several
core mechanisms of depressive physiopathology, including glutamatergic transmission in the limbic
system and cerebral cortex [89], regulation of the HPA axis [41,90], inflammation and oxidative
stress [91], response to NMDA receptor antagonist [92], serotonin, dopamine, and noradrenaline
modulation [43], BDNF expression [40], as well as the modulation of the sleep–wake cycle [93].
Moreover, previous evidence reported that the potential efficacy of magnesium in depression may
be linked to the modulation of glutamatergic signals, which play a key role on neuroprotection,
and to the fact that magnesium acts as antagonist to NMDA receptors [42]. Moreover, evidence also
showed that magnesium may have a synergistic effect when combined with antidepressants. Indeed,
the review carried out by Serefko et al. (2016) suggested that magnesium could improve the
efficacy of standard antidepressant treatments, and as such, could be an add-on treatment to the
standard antidepressant [94]. The role of magnesium in depression has been also demonstrated in
several preclinical studies. Interestingly, Poleszak et al. (2005) found that magnesium enhanced
the antidepressant effect of imipramine in mice using a forced swim test (FST) [95]. Additionally,
the same research group, in 2006, showed that combining sub-therapeutic doses of Mg2+ in combination
with sub-therapeutic doses of imipramine leads to a significant antidepressant-like effect in animal
models [96]. Furthermore, Singewald et al. (2004) demonstrated that imipramine could reverse
depression-like behavior in rats with low levels of magnesium [97]. In addition, Poleszak et al. (2007),
demonstrated that magnesium administered in combination with an NMDA antagonist called MK-801,
which is similar to ketamine, amplified its antidepressant effect [98]. More recently, Murck et al. (2013)
reported that magnesium and ketamine showed an overlap of action in animal models because of
both of them could lead to synaptic sprouting [99], ultimately suggesting that they both have a similar
action in SNC. Thus, the authors suggested that, in depressed patients, magnesium levels could be
used to predict the effect of ketamine [99].
Therefore, based on this evidence, showing the key role of magnesium in influencing mechanisms
that may lead to depression, further studies investigating the impact of antidepressant drugs on
intracellular magnesium concentration in neurons are required.
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Interestingly, the research carried out on depression highlighted the linked between the
development of this disabling illness and reduced plasmatic levels of magnesium, evidence that is line
with previous reviews and meta-analyses [25]. In the light of these results, several studies [54,56,64]
suggested that, for adults seen in primary care, lower serum magnesium levels were associated with
depressive symptoms, ultimately supporting the use of supplemental magnesium as a therapy. For this
reason, magnesium could be considered a hallmark of pathology or could represent a biomarker of
response to drug treatment in patients with mood disorders, as also reported by a previous review [79].
Indeed, patients with therapy refractory depression appear to have lower central nervous system
magnesium levels in comparison to health controls [61]. In an attempt to develop nutrition therapies
for depressed patients with lower levels of magnesium, it could be useful to use a dose of this mineral
combined with the standard antidepressant treatment to ameliorate the outcomes of the disease,
providing a personalized approach to depression.
However, only a handful of studies investigated the efficacy of magnesium supplementation alone
or as an add-on therapy to other drugs In particular, it emerged from these studies that magnesium
alone [77,78,83], magnesium and other micronutrients [80], magnesium with vitamin B6 [82] or
magnesium in combination with antidepressants [79] could not be considered significantly effective for
treating depression, since the results are conflicting. Interestingly, Medhi et al. (2017) [83], was the only
study that administered an intravenous infusion of magnesium and reported that this formulation had
only a partial, but insignificant, anti-depressive effect in depressed patients. A possible explanation
could be due to the particular pharmacokinetics of magnesium. Indeed, the total concentration
of magnesium is mainly intracellular and free ion concentration does not always correlate with
whole concentration.
Importantly, comorbidities and other confounders, such as age and geographic location,
may contribute to the discrepant findings. In addition, other factors linked to psychiatric patients could
impact on these findings, such as sedentary lifestyle, unhealthy dietary patterns, smoking, alcohol or
substance abuse and lower compliance with treatments.
Similarly, the evidence reporting the relationship between anxiety disorders and magnesium are
still conflicting, although this association is well established in the scientific literature [100]. However,
these negative results might be due to the small number of studies investigating magnesium values in
anxiety disorders in the past 10 years, ultimately suggesting the need for future research focusing on
elucidating magnesium’s mechanism of action in order to determine if it has anxiolytic properties.
Furthermore, mixed results have also been reported by studies investigating the link between
dietary pattern and the deficiency of magnesium or other minerals (e.g., Zn, Fe) in ADHD patients,
with some studies showing an efficacy and other not. However, it is possible that these heterogenous
results could be linked to the different minerals supplemented, meaning that we were unable to
examine the real effect of each mineral, and also to different characteristics of patients enrolled in the
original studies, which were not homogeneous in terms of age, severity and subtype of ADHD.
Finally, due to the paucity of studies investigating ASD, SCZ and OCD, at present is not possible
to determine the role of magnesium in either the physiopathology or in the treatment of these disorders.
Similarly, regarding eating disorders, we found only one study where the presence of various internal
conditions seems to mask the pathophysiological role of magnesium. This represents an unexplored
field and could be interesting in elucidating the role and effect of magnesium in these disorders.
Importantly, this review might be considered in the light of some limitations derived from the
heterogeneity of the included studies in terms of (1) types of magnesium supplementation, (2) target
population (3), follow-up period, (4) outcome measures, (4) the severity of the illness (5) sample sizes,
(6) comorbidities and (7) lifestyle. All these factors may have limited the generalizability of the results
and made it difficult to compare the results emerged from the available studies.
In conclusion, due to the lack of consistency between the available studies, there is limited
evidence that magnesium, alone or as an add-on therapy, is useful in treating different psychiatric
disorders, even if a large amount of data showed reduced plasma levels, especially in depressive
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patients. Therefore, larger and more homogenous studies are required for showing the role and the
effects of magnesium in psychiatric illnesses.
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